Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Recent Videos
Related Content
Study: No significant long-term benefits found in cocoa extract for AMD

Study: No significant long-term benefits found in cocoa extract for AMD

Lynda Charters
March 31st 2025
Article
Opthea discontinues COAST and ShORe trials in wet AMD

Opthea discontinues COAST and ShORe trials in wet AMD

Martin David Harp
March 31st 2025
Article
Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint

Martin David Harp
March 25th 2025
Article
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

Lynda Charters
March 19th 2025
Article
The future of retina: New targets and more durable solutions

The future of retina: New targets and more durable solutions

Robin Vora, MD;Hannah El-Sabrout
March 18th 2025
Article
4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD

4DMT enrolls first patient in phase 3 4FRONT-1 evaluating 4D-150 for the treatment of wet AMD

Martin David Harp
March 11th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.